Longitudinal Outcomes and Monitoring of Patients With Multisystem Inflammatory Syndrome in Children

Michael A. Fremed* and Kanwal M. Farooqi

Division of Pediatric Cardiology, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian-Morgan Stanley Children’s Hospital, New York, NY, United States

The acute manifestations and short-term outcomes of multisystem inflammatory syndrome (MIS-C) have been extensively described; however, our understanding of the longitudinal outcomes associated with this condition continue to evolve. Here we review the existing literature on outcomes of MIS-C up to 1 year following diagnosis and summarize current published expert recommendations for management and follow up of these patients.

Keywords: longitudinal outcomes, multisystem inflammatory syndrome in children, COVID-19, myocarditis, pandemic

INTRODUCTION

The multisystem inflammatory syndrome in children (MIS-C) is now a well described phenomenon associated with novel coronavirus 2019 disease (COVID-19) (1–9). It primarily impacts children following SARS-CoV-2 infection, though a similar phenomenon has more recently been described in adults (10). Cardiac injury in addition to gastrointestinal manifestations is a predominant feature of this condition, with up to 80% of MIS-C cases involving cardiac insult (2, 4, 11). Common gastrointestinal symptoms include abdominal pain, emesis, and diarrhea. Additionally, many of these patients require admission to the intensive care unit as well as vasoactive support at rates more than 5 times that of patients with severe acute COVID-19 (12).

More recently, the focus has shifted toward follow up of these patients and long-term complications associated with MIS-C, though the existing data on outcomes post-discharge in these patients is limited. Here, we summarize the current literature on post-discharge outcomes in children with MIS-C and use this evidence to provide expert opinion-based recommendations for how to monitor and manage these patients in both acute and post-acute time periods.

ACUTE MIS-C

The acute presentation of MIS-C is defined by the Centers for Disease control as fever, laboratory evidence of inflammation, hospitalization for clinically severe illness in individuals under 21 years of age with positive SARS-CoV-2 testing (PCR, serology, or antigen) with two or more organ systems involved for which there is no plausible alternative diagnosis (13). Cardiac injury has consistently been shown to be a key feature of this condition. The findings from the largest cohorts of MIS-C patients are summarized in Table 1. In one of the larger multicenter studies characterizing this disease, Feldstein et al. (2) reported on 216 children with MIS-C. In this cohort, 92% of patients
had gastrointestinal manifestations and 80% demonstrated cardiac involvement. Hematologic abnormalities were present in 76% of patients, mucocutaneous findings were present in 74% of patients, and respiratory system was involved in 70% of patients. Specific cardiac manifestations of MIS-C include elevated troponin and NT-proBNP (2, 3, 11, 14) ventricular dysfunction, myocarditis/pericarditis, arrhythmia, ECG abnormalities including first degree atrioventricular block (15), prolonged QTc, T wave abnormalities, and ST segment changes, and pericardial effusions, among others (2, 3, 11, 15–17).

Studies of echocardiographic findings have shown ventricular systolic dysfunction in ~40–60% of patients with acute MIS-C (2, 11, 12, 18, 19) as well as evidence of diastolic dysfunction, even in the absence of systolic dysfunction. Coronary artery abnormalities such as aneurysm and dilation have been demonstrated but are less common than in classic Kawasaki disease (20). Left ventricular global longitudinal strain may be abnormal even in the absence of clinically apparent cardiac symptoms and left ventricular systolic dysfunction (21). Abnormal strain has been shown to be associated with increased odds of vasoactive support requirement, duration of vasoactive support, and ICU length of stay (22). An association has also been shown between degree of inflammation and cardiac injury severity, in particular CRP and NT-proBNP (11). Abnormal strain has also been associated with greater number of organ systems involved (23).

In a 2020 systematic review, Ahmed et al. (24) reported on 39 observational studies of MIS-C patients encompassing the period January 1st 2020 to July 25th 2020. Out of 662 patients, 71% required admission to the intensive care unit (ICU). Mechanical ventilation was utilized in 22% of these patients and 4% required extracorporeal membrane oxygenation (ECMO). Notably, nearly half of these patients had underlying comorbidities, with obesity present in 50% of those with comorbidities. Plasmapheresis has also been utilized as a treatment option for MIS-C (25), with one small prospective trial showing a significant decrease in organ dysfunction in those who underwent plasmapheresis in addition to steroids and intravenous immune globulin (IVIG) as compared to those who received steroids and IVIG only (26).

Gastrointestinal manifestations are common in MIS-C and are part of the initial presentation in up to 90% of cases. Symptoms can range from more mild nausea, vomiting, or diarrhea to more severe involvement, such as appendicitis, pancreatitis, hepatitis or hepatomegaly, intussusception, biliary sludge or cholecystitis, ascites, ileitis or colitis, abdominal fluid collections, and mesenteric adenitis (12, 25, 27, 28). Valverde et al. (4) looked at 286 patients with MIS-C, 159 of whom underwent abdominal ultrasound. Of those who underwent ultrasound, 39% had abnormal abdominal findings including ascites in 21%, lymphadenopathy in 14%, ileitis in 9%, and colitis in 4%.

The immunological profile of this disease is similar to that of Kawasaki disease with some notable exceptions. Lymphocytopenia and thrombocytopenia suggestive of bone marrow suppression are common in the acute phase of MIS-C, as opposed to Kawasaki disease, where thrombocytosis is more common than thrombocytopenia and CRP may not be as elevated (29). Syrimi et al. (30) performed deep immune profiling of the various stages of MIS-C and showed that in addition to the neutrophilia there is higher activation of monocytes, memory CD8+T cells, T-cells, B-cell plasmablasts, and double negative B-cells. Additionally, they found high IL-6 and systemic complement activation with high C5b-9 levels. Because MIS-C is believed to be an immune-mediated phenomenon that triggers a hyper-inflammatory response, management has largely relied on antagonists of various components of the immune system (31). Treatment of MIS-C has typically involved steroids, IVIG, and/or anakinra, an IL-1 inhibitor (32). Aspirin is also commonly used, in particular when there is concern for coronary artery involvement, similar to treatment for Kawasaki disease (33).

Despite the illness severity in these patients, mortality is low with reported rates around 2% (24) with 1 case report of sudden cardiac death occurring in a patient after initial clinical improvement after MIS-C (34). In a large multicenter study of 112 COVID-19 related deaths in children under age 21, McCormick et al. found that only 14% of deceased patients met criteria for MIS-C. Mortality after MIS-C was more likely to occur in previously healthy patients while mortality due to non-MIS-C COVID-19 was more likely in those with underlying comorbidities (35).

Several prognostic indicators have been suggested based on the available evidence. In an outcomes study of 76 patients with MIS-C, Haslak et al. showed that those admitted to the pediatric ICU were generally older in age and had lower albumin on admission. Higher procalcitonin was also associated with longer hospital length of stay (25). Similar findings were reported by Abrams et al. in a large, retrospective surveillance study, in which they reviewed 1,080 cases of MIS-C. They found that the odds of ICU admission were greatest in those 13–20 years old and non-Hispanic Black patients. Shortness of breath, abdominal pain on presentation, decreased ventricular function, shock, or myocarditis were all associated with higher rates of ICU admission (36). Recent reports from the CDC and Levy et al. suggest a significant protective effect of mRNA based COVID-19 vaccination in children 12 years and older against development of MIS-C, especially in severe cases (37, 38).

**LONGITUDINAL OUTCOMES FOLLOWING MIS-C (TABLE 2)**

**Immunological**

Rapid normalization of both inflammatory markers and cardiac injury biomarkers has been demonstrated following the acute phase of the illness. Laboratory abnormalities including NT-proBNP, troponin-T, lymphocytopenia, thrombocytopenia, and C-reactive protein (CRP) appear to return to normal ranges by 1–4 weeks post discharge (11). In a study of 1 year outcomes of UK patients with MIS-C, Davies et al. reported that 50% of patients demonstrated normalization of lymphocytes and neutrophils within a few days post-admission, CRP within 11 days, and ferritin and D-dimer within 3 weeks. At 1 year post-admission, only 2% of patients had still not demonstrated normalization of lymphocytes, neutrophils, and platelet count. D-dimer remained...
### TABLE 1 | Acute Outcomes in Patients with MIS-C.

| Demographics | Feldstein et al. (n = 539) | Haslak et al. (n = 76) | Valverde et al. (n = 286) | Ahmed et al. (n = 662) |
|--------------|---------------------------|------------------------|--------------------------|-----------------------|
| **Age (years)** | 8.9 | 8.2 (±4.4) | 8.4 (IQR 3.8–12.4) | 9.3 ± 0.5 |
| **Male** | 58 | 55 | 68 | 52 |
| **Underlying comorbidity** | 31 | 16 | 6 | 48 |
| **Organ system involved** | | | | |
| Any cardiovascular | 67 | 93 | NA | 54 |
| Mitral valve regurgitation | NA | 47 | 42 | 3 |
| Tricuspid valve Regurgitation | NA | NA | 6 | NA |
| Systolic dysfunction | 34 | 18 | 38 | 45 |
| Coronary artery dilation/aneurysm | 13 | 8 | 24 | 16 |
| Pericardial Effusion/Pericarditis | 25 | 17 | 21 | 22 |
| Gastrointestinal | 90 | 50 | 71 | 74 |
| Dermatologic | 67 | 53 | 63 | 56 |
| Respiratory | 80 | 45 | 56 | NA |
| **Admission characteristics** | | | | |
| ICU | 74 | 33 | 57 | 71 |
| Vasoactives/inotropes | NA | 29 | NA | 52 |
| **Hospital LOS (days)** | 7 (IQR 5–11) | 8 (Range 2–22) | 10 (IQR 3–7) | 7.9 ± 0.6 |
| **Respiratory support** | | | | |
| Supplemental oxygen only | NA | 14 | NA | NA |
| Non-invasive ventilation | 36 | 12 | NA | 7 |
| Invasive mechanical ventilation | 18 | 4 | 15 | 22 |
| ECMO | 3 | NA | ≤1% | 4 |
| Death | 2 | 1 | ≤1% | 2 |
| **Treatment** | | | | |
| IVIG | 77 | 100 | 78 | 76 |
| Steroids | 70 | 97 | 28 | 52 |
| Anticoagulation | 63 | 92 | 38 | 26 |
| Anakinra | NA | 4 | NA | 9 |
| Plasmapheresis | NA | 18 | NA | NA |
| Antibiotics | NA | NA | 71 | 16 |
| Antplatelet | 57 | NA | 74 | 17 |

*Numbers represent % of sample unless otherwise stated. Continuous variables are reported as median (IQR or Range) or mean ± standard deviation. Categorical variables are reported as percent of study sample. ECMO, Extracorporeal membrane oxygenation; IVIG, Intravenous immune globulin. *Feldstein et al. (n = 539)- only percentages of severe outcomes are reported in this study.*

abnormal in 25% of patients and Ferritin remained abnormal in 17% of patients at 1 year (39).

### Cardiovascular

In one of the first studies to report on long term follow up following MIS-C, Farooqi et al. (11) followed 45 patients up to 9 months following diagnosis. Despite an 80% prevalence of at least mild and 44% prevalence of at least moderate-severe echocardiographic abnormalities, only 18% had residual mild abnormalities by 1–4 week follow up. NT-proBNP and Troponin-T normalized in most patients by 1–4 weeks. Of the 24 patients who returned for 4–9 month follow up, only 2 patients had remaining echocardiographic abnormalities: 1 with mild ventricular dysfunction and 1 with mild atrioventricular valve regurgitation. Kobayashi et al. (23) showed that left ventricular strain may remain abnormal even after normalization of left ventricular ejection fraction; however, a mid-term longitudinal study by Matsubara et al. (40) demonstrated that several strain parameters rapidly improve in the first week following presentation then continue to improve more gradually through 3–4 months. In their study, abnormalities in multiple strain parameters were worse in those with biochemical evidence of cardiac injury such as elevated troponin or BNP; however, they also improved more rapidly and normalized within the same time period as those without biochemical evidence of cardiac injury.

Capone et al. (18) conducted a similar study following 50 MIS-C patients over a 6-month period at intervals of 2, 8 weeks, and 6 months post-discharge. During the acute phase, 52% of subjects...
demonstrated evidence of left ventricular systolic dysfunction on echocardiogram and 32% showed evidence of left ventricular diastolic dysfunction, and 24% had coronary artery aneurysm or dilation. By 2 weeks, left ventricular systolic dysfunction was present in only 1 patient (2%) and coronary artery abnormalities were present in 3 patients (6%) with complete resolution by 8 weeks. Despite these rapid improvements, diastolic dysfunction persisted in 11% at 2 weeks, 9% at 8 weeks, and 4% at 6 months. Penner et al. (14) found that nearly all cardiac abnormalities including serum biomarkers and ventricular dysfunction normalized by 6 weeks post-diagnosis, with only 1 patient demonstrating persistent large coronary artery aneurysm at 6 weeks, with no change in size at 6 months, and 1 pericardial effusion. An additional patient demonstrated persistent but improved coronary artery dilation at 6 months.

Davies et al. (39) reported on a cohort of MIS-C patients 1 year after their initial admission to the ICU and found that ventricular dysfunction resolved by day 74 post-admission. Out of 19 coronary artery aneurysms, 14 had resolved at 1 year follow up, as did 9/10 “bright” coronary arteries. The remaining patient with bright coronary arteries progressed to an aneurysm. There was no evidence of ventricular dysfunction in any patient after 50 days post-admission and 75% of patients had normalization of function by day 21 post-admission.

Because of the severity of cardiac injury seen during the acute phase of MIS-C, cardiac MRI (CMR) has become a useful imaging modality in this population. Despite the myocarditis like presentation, MIS-C differs from classic viral myocarditis in that it appears to be predominantly, if not purely, a post-infectious inflammatory mediated process. Several studies have looked at cardiac MRI findings in patients following hospitalization for MIS-C. Some of these have found findings consistent with myocardial edema. However, most have not shown evidence of the necrosis, fibrosis, or late gadolinium enhancement that is typically seen in cases of classic viral myocarditis on studies performed 8 days to 3 months post-diagnosis (18, 41–44). It is possible that when fibrosis does occur it is more common in the first 2 weeks following diagnosis as compared to later periods, as demonstrated in a study by Matsubara et al. In this report, 2/14 (14%) CMR showed evidence of fibrosis (as well as edema), performed at 6 and 10 days post-diagnosis, respectively. Both of these patients had no evidence of left ventricular dysfunction by conventional echocardiography, strain, or CMR. Although CMR appears to be normal in most cases following resolution of acute illness, one small case series of CMR findings in patients with MIS-C did show late gadolinium enhancement in two patients at 50 days and 3.5 months following diagnosis (45). Similarly, in a small prospective controlled study of CMR findings in children following COVID-19 or MIS-C, Webster et. al. found no evidence of myocardial injury in CMR findings compared with healthy controls (46). Similar CMR findings are described in adults with multisystem inflammatory syndrome, with myocardial edema being the predominant finding and fibrosis or necrosis a more rare abnormality (47). These findings suggest that the cardiac injury associated with MIS-C is a result of a transient hyperinflammatory process and that long term abnormalities and cardiac injury is likely rare.

Gastrointestinal
Penner et al. (14) reported outcomes from 46 patients in the UK up to 6 months following MIS-C. They found that gastrointestinal symptoms including abdominal pain, diarrhea, nausea and vomiting resolved by this time point. Fecal calprotectin was elevated in 7% of patients for whom this data was available. On abdominal imaging, 20% of patients had abnormalities at 6 weeks including ileitis, colitis, liver inflammation, and splenomegaly, with 1 patient experiencing persistent splenomegaly at 6 months post-diagnosis. One patient underwent colonoscopy and gastroscopy and demonstrated eosinophilic inflammatory changes in the colon and ileum. Liver enzymes continued to rise through 6 weeks before normalizing. Additionally, the median BMI continued to increase through the 6 month follow up (Table 2).

Quality of Life
In the same 1 year follow up study, Penner et al. performed quality of life assessments using the validated PedsQL (48) assessment. They found severe impairment in physical functioning in up to 13% of participants. Emotional lability was present in 26% at 6 weeks and 15% at 6 months. Assessment with the Pediatric Index of Emotional Distress (49) showed 7% of patients scored above the cutoff for high risk of significant distress. Parental anxiety regarding possibility of MIS-C relapse was high (31%). Despite these concerns, 73% of parents indicated some degree of hesitancy with regards to COVID-19 vaccination. Nearly all children were back in school by 6 months post-diagnosis (14).

RETURN TO PHYSICAL ACTIVITY FOLLOWING MIS-C
Given the high incidence of cardiac injury including myocardial dysfunction associated with MIS-C, a major concern following resolution of the acute illness has been returning to physical activity including both organized competition as well as routine daily activities. Current recommendations have adopted the clinical recommendations for traditional myocarditis to guide management in these patients, which includes exercise restriction for 3–6 months (50–52); however, given the growing MRI evidence that this is not the same as the typical myocarditis, this may warrant additional consideration in the future. Even in the absence of clinical evidence of myocardial injury, deconditioning has been demonstrated in healthy children likely due to increased sedentary behavior during periods of quarantine and lockdowns, with studies showing decreased performance on cardiopulmonary exercise testing and 6-min walk testing. In their 1 year follow up study, Penner et al. found that 65% of MIS-C patients were below the 3rd percentile for distance at 6 weeks and 45% of patients were below the 3rd percentile for distance at 6 months. Regardless, all patients with MIS-C should undergo cardiology consultation prior to discharge (if admitted) with regular outpatient cardiology follow up post discharge and should be
TABLE 2 | Longitudinal Outcomes MIS-C.

|                  | Farooqi et al. (n = 45) | Capone et al. (n = 50) | Barris et al. (n = 16) | Penner et al. (n = 46) | Matsubara et al. (n = 60) |
|------------------|-------------------------|-----------------------|-----------------------|------------------------|--------------------------|
| Follow up (months) | 5.8 (IQR 1.3–6.7)       | 6–8                   | 7 (IQR 6.0–8.4)       | 6                      | 3–6                      |
| **Cardiovascular** |                         |                       |                       |                        |                          |
| **Any echo abnormality (at least mild)** |                         |                       |                       |                        |                          |
| Admission        | 80                      | 66                    | NA                    | 33                     | NA                       |
| Short Term       | 18                      | 21                    | NA                    | NA                     | NA                       |
| Mid Term         | 8                       | 4                     | NA                    | 4                      |                          |
| **Tricuspid Valve regurgitation** |                         |                       |                       |                        |                          |
| Admission        | 27                      |                       | NA                    | NA                     |                          |
| Short Term       | 60                      |                       | NA                    | NA                     |                          |
| Mid Term         | 15                      |                       | NA                    | NA                     |                          |
| **Mitral valve regurgitation** |                         |                       |                       |                        |                          |
| Admission        | 36                      |                       | NA                    | NA                     | NA                       |
| Short Term       | 78                      |                       | NA                    | NA                     | NA                       |
| Mid Term         | 4                       |                       | NA                    | NA                     |                          |
| **Left ventricular systolic dysfunction** |                         |                       |                       |                        |                          |
| Admission        | 49                      | 52                    | 44                    | NA                     | NA                       |
| Short term       | 10                      | 2                     | 13                    | NA                     | NA                       |
| Mid term         | 4                       | 0                     | 0                     | 0                      | 0                        |
| **Coronary artery dilation or aneurysm** |                         |                       |                       |                        |                          |
| Admission        | 16                      | 24                    | 19                    | 7                      |                          |
| Short term       | 0                       | 2                     | 6                     | 4                      | 2                        |
| Mid term         | 0                       | 0                     | 6                     | 4                      | 0                        |
| **Pericardial effusion** |                         |                       |                       |                        |                          |
| Admission        | 44                      |                       | NA                    | 2                      |                          |
| Short term       | 10                      |                       | NA                    | 2                      |                          |
| Mid term         | 0                       |                       | NA                    | 2                      |                          |
| **CMR performed** | NA                      | 22                    | 56                    | NA                     | 23                       |
| Timing of MRI (post-admission) | NA                      | 2–4 weeks | 9.4 (Range: 8.8–10.0) months | NA | 5 days–9.5 months |
| **Myocardial edema** | NA                      | 0                     | 44                    | NA                     | 21                       |
| **Fibrosis**     | NA                      | 0                     | 0                     | NA                     | 14                       |
| **6-min walk exercise test (abnormal)** |                       |                       |                       |                        |                          |
| 6 weeks          | NA                      | NA                    | NA                    | 65                     | NA                       |
| 6 month          | NA                      | NA                    | NA                    | 45                     | NA                       |
| **Gastrointestinal** |                       |                       |                       |                        |                          |
| Symptoms         | NA                      | NA                    | NA                    | 98                     | NA                       |
| Significant imaging findings | NA                  | NA                    | NA                    | 13                     | NA                       |
| **Labs (weeks to normalization post-discharge)** |                       |                       |                       |                        |                          |
| Troponin         | 1–4                     | 2                     | NA                    | 6                      | NA                       |
| BNP              | 1–4                     | 2                     | NA                    | 6                      | NA                       |
| Platelets        | 0                       | 8                     | NA                    | 6                      | NA                       |
| CRP              | 1–4                     | 2                     | NA                    | 6                      | NA                       |

NA, not available.
Numbers represent % of sample unless otherwise stated. Continuous variables are reported as median (IQR or Range) or mean ± standard deviation. Categorical variables are reported as percent of study sample.

cleared by a cardiologist prior to returning to physical activity. Once cleared, they should undertake a gradual approach over a minimum of a 7 day period before returning to full intensity and duration (52–54).

**CURRENT RECOMMENDATIONS**

The American College of Rheumatology published guidance on the management of patients with MIS-C (32) and more...
recently submitted an updated version for publication, available on their website (55). In this report they recommend a basic lab workup for all children under investigation for MIS-C including complete blood count, complete metabolic panel, ESR, CRP, and SARS-CoV-2 testing (PCR and/or serology). If the results of this initial screening round of testing are suspicious for MIS-C or the patient experienced shock of unclear etiology, additional testing should be obtained including additional acute phase reactants, cardiac enzymes such as BNP and troponin T, SARS-CoV-2 serology if not already obtained, peripheral blood smear, ECG, and echocardiogram. If a diagnosis of MIS-C is made, patients with mild symptoms may be appropriate to manage with close monitoring only. For those requiring hospitalization, first line therapy should include both IVIG 2 gm/kg and steroid therapy. Iffevers and/or end-organ damage persists despite initial treatment, intensification treatment should be provided with high dose steroids, anakinra, or infliximab. As of the time the guidance was published, they did not recommend tocilizumab or other immunomodulatory agents due to insufficient evidence unless glucocorticoids and anti-IL1 therapies are contraindicated or the illness refractory to these therapies.

For those patients with abnormal cardiac biomarkers on admission, BNP and/or troponin T should be trended until normalized. ECGs should be performed at least every 48 h during admission and followed up post-discharge, with continuous telemetry in the event of abnormal ECG findings as well as home ambulatory monitoring. Echocardiography should be performed at diagnosis, as clinically indicated during admission, and repeated at 1–2 and 4–6 weeks following presentation with possible 1 year follow up. A cardiac MRI should be considered 2–6 months post-diagnosis for those patients with significant left ventricular dysfunction. Cardiac CT should be performed on patients for whom there is suspicion of coronary artery abnormalities but are not able to be visualized adequately by echocardiography.

With regards to thromboprophylaxis, the ACR recommends low dose-aspirin for all patients with MIS-C until normalization of the platelet count. Patients with coronary artery aneurysms with Z scores >10 should also receive enoxaparin or warfarin. Those at higher risk for thromboembolic events including patients with central venous lines, age >12 years, malignancy, admitted to the ICU, severely depressed left ventricular dysfunction, and markedly elevated D-dimer values should also be considered for higher intensity anticoagulation.

At our institution, we have a dedicated MIS-C follow up team consisting of pediatric cardiologists with follow up visits conducted at 2, 6 weeks, 6 months, and 1 year following diagnosis. Bloodwork, ECG, and echocardiography are performed at each visit and patients are exercise restricted for 3–6 months. CMR is performed in the acute phase of MIS-C if mild or more significant left ventricular dysfunction is present (ejection fraction ≤50%) and in all patients at 6 months following diagnosis. Longitudinal outcomes studies are ongoing with patients expected to be followed through at least 1-year post-discharge and potentially longer. Large, federally funded multi-center trials are also underway including the NIH sponsored Long-terM OUtcomes after the Multisystem Inflammatory Syndrome in Children (MUSIC) study, which aims to follow at least 600 patients across North America for 2 years following initial MIS-C presentation (56). The MIS-C population will also be included in the NIH RECOVER program, a large scale research initiative designed to study post-acute sequelae of COVID-19, which includes MIS-C and “Long-COVID” (57).

CONCLUSIONS

MIS-C is a severe consequence of COVID-19 in children that is associated with significant hemodynamic and cardiovascular compromise. The acute presentation of MIS-C typically includes hypotension, fever, elevated inflammatory markers, gastrointestinal and cardiac manifestations that require management in the intensive care unit. Despite the severity of initial presentation, most abnormalities appear to quickly resolve within the first few weeks. In addition, despite clinically presenting with a myocarditis-like picture, findings on CMR that are consistent with myocarditis such as myocardial fibrosis are rare. Though we continue to expand our knowledge of this condition, providers should continue to take a cautious approach to the management of this patient population until the long-term outcomes following MIS-C are more completely understood. The results from various federally funded research initiatives studying long-term outcomes in this patient population will be crucial to our understanding of this disease and will allow for more definitive clinical guidelines for management of these patients.

AUTHOR CONTRIBUTIONS

MF and KF contributed to conception and design of the study and contributed meaningfully to the writing and revision of the manuscript in its submitted form. All authors contributed to the article and approved the submitted version.

FUNDING

This publication was supported in part by Genentech ML42866 and by 3U01AI100119-09S1.

REFERENCES

1. Kim L, Whitaker M, O’Halloran A, Kambhampati A, Chai SJ, Reingold A, et al. COVID-NET Surveillance Team. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep. (2020) 69:1081–8. doi: 10.15585/mmwr.mm6932e3

2. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MRF, et al. Overcoming COVID-19 Investigators CDC COVID-19 Response Team. Multisystem inflammatory syndrome in us children and adolescents. N Engl J Med. (2020) 383:334–46. doi: 10.1056/NEJMoA2021680

3. Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem Inflammatory Syndrome Related to COVID-19 in
Previously Healthy Children and Adolescents in New York City. JAMA. (2020) 324:294–6. doi: 10.1001/jama.2020.10374
4. Valverde I, Singh Y, Sanchez-de-Toledo J, Theocharis P, Chikermane A, Di Filippo S, et al. Acute cardiovascular manifestations in 286 children with multisystem inflammatory syndrome associated with COVID-19 infection in Europe. Circulation. (2021) 143:21–32. doi: 10.1161/CIRCULATIONAHA.120.043853
5. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AL Fischer A, et al. Columbia Pediatric COVID-19 Management Group. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. JAMA Pediatr. (2020) 174:e202430. doi: 10.1001/jamapediatrics.2020.2430
6. Spencer R, Closson RC, Gorelik M, Boneparth AD, Hough RF, Acker KP, et al. COVID-19-associated inflammatory syndrome with clinical features resembling Kawasaki Disease. Pediatrics. (2020) 146:e20201845. doi: 10.1542/peds.2020-1845
7. Verdino L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. (2020) 395:1771–8. doi: 10.1016/S0140-6736(20)31103-X
8. Cattalini M, Della Paolera S, Zunica F, Bracaglia C, Giangreco M, Verdino L, et al. Rheumatology Study Group of the Italian Pediatric Society. Defining Kawasaki disease and pediatric inflammatory multisystem syndrome temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national multicenter survey. Pediatr Rheumatol Online J. (2020) 18:72. doi: 10.1186/s12969-021-00511-7
9. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Acute cardiovascular manifestations in 286 children with COVID-19-related multisystem inflammatory syndrome in children and Kawasaki Disease. JAMA Netw Open. (2021) 4:e2139974. doi: 10.1001/jamanetworkopen.2021.3974
10. Morris SB, Schwartz NG, Patel P, Abbo L, Beauchamps L, Balan S, et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine. (2020) 26:100527. doi: 10.1016/j.eclinm.2020.100527
11. Haslak F, Barut K, Durak C, Akyeveli Y, Yildiz M, Gulyasev V, et al. Clinical features and outcomes of 76 patients with COVID-19-related multisystem inflammatory syndrome in children. Clin Rheumatol. (2021) 40:4167–78. doi: 10.1007/s10067-021-03570-x
12. Eremak S, Oscan S, Perk O, Uyar E, Çelikel Acar B, K Gibraltar E, et al. Therapeutic plasma exchange: A potential management strategy for critically ill MIS-C patients in the pediatric intensive care unit. Transfus Apher Sci. (2021) 60:103119. doi: 10.1016/j.transci.2021.103119
13. Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis KG. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to coronavirus disease 2019: a single center experience of 44 cases. Gastroenterology. (2020) 159:1571–4.e2. doi: 10.1053/j.gastro.2020.05.079
14. Lo Vecchio A, Garazzino S, Smarrazzo A, Venturini E, Poeta M, Berlese P, et al. Italian STITIP-SIP Paediatric SARS-CoV-2 Infection Study Group. Factors associated with severe gastrointestinal diagnoses in children with SARS-CoV-2 infection or multisystem inflammatory syndrome. JAMA Netw Open. (2021) 4:e2139974.
15. Lee MS, Liu YC, Tsai CC, Hsu JH, Wu JR. Similarities and differences between COVID-19-related multisystem inflammatory syndrome in children and Kawasaki Disease. Front Pediatr. (2021) 9:604118. doi: 10.3389/fped.2021.604118
16. Syrimi E, Fennell E, Richter A, Vrljicak P, Stark R, Ott S, et al. The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery. iScience. (2021) 24:103215. doi: 10.1016/j.isicience.2021.103215
17. Sukwan W, Chupradit S, Yumaseh AV, Ravali S, Shalaby MN, et al. Immunotherapy of multisystem inflammatory syndrome in children (MIS-C) following COVID-19 through mesenchymal stem cells. Int Immunopharmacol. (2021) 101:108217. doi: 10.1016/j.intimp.2021.108217
18. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19. Version 2. Arthritis Rheumatol. (2021) 73:e13–29. doi: 10.1002/art.41616
19. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Multisystem inflammatory syndrome in children (MIS-C) from acute disease to recovery. JAMA. (2022) 327:2363–75. doi: 10.1001/jama.2022.212710
20. Matsuura D, Kauffman HL, Wang Y, Calderon-Ayrosa R, Nadaraj S, Elias MD, et al. Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19 in the United States. J Am Coll Cardiol. (2020) 76:1947–61. doi: 10.1016/j.jacc.2020.08.056
21. Ahmed S, Strait K, RayChaudhuri N, Gendi SM. Global longitudinal strain reduction in the absence of clinical cardiac symptoms in multisystem inflammatory syndrome in children associated with COVID-19: a case series. Pediatr Cardiol. (2022) 43:233–7. doi: 10.1007/s00246-021-02712-z
22. Basu S, Kim EL, Shannon MP, Austin A, Pollack MM, Harahsheh AS, et al. Strain echocardiography and myocardial dysfunction in critically Ill children with multisystem inflammatory syndrome unrecognized by conventional echocardiography: a retrospective cohort analysis. Pediatr Crit Care Med. (2022) 23:145–52. doi: 10.1097/PCC.0000000000002850
23. Kobayashi R, Dionne A, Ferraro A, Harrild D, Newburger J, VanderPluym C, et al. Detailed assessment of left ventricular function in multisystem inflammatory syndrome in children, using strain analysis. CJF Open. (2021) 3:880–7. doi: 10.1016/j.cjfo.2021.02.012
24. Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: a systematic review. EJCI. (2020) 26:100527. doi: 10.1016/j.eclinm.2020.100527
25. Venkatesha GA, Srinivas N, Mohamedali S, Chandrasekar S. Sudden cardiac death in a young boy with multisystemic inflammatory syndrome in children (MIS-C) from acute disease to recovery. BMJ Case Rep. (2021) 2021:2021052273. doi: 10.1542/peds.2021-052273
36. Abrams JY, Oster ME, Godfred-Cato SE, Bryant B, Datta SD, Campbell AP, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. *Lancet Child Adolesc Health*. (2021) 5:323–31. doi: 10.1016/S2542-4642(21)00050-X

37. Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021. *MMWR Morb Mortal Wkly Rep*. (2022) 71:52–8.

38. Levy M, Recher M, Hubert H, Javouhey E, Fléchelles O, Leteurtre S, et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. *JAMA*. (2022) 327:281–3. doi: 10.1001/jama.2022.23262

39. Davies P, du Pré P, Lillie J, Kanthimathinathan HK. One-year outcomes of critical care patients post-COVID-19 multisystem inflammatory syndrome in children. *JAMA Pediatr*. (2021) 175:1281–3. doi: 10.1001/jamapediatrics.2021.2993

40. Matsubara D, Chang J, Kaufman HL, Wang Y, Sileo C, et al. Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19. *Radiology*. (2020) 297:E283–8. doi: 10.1148/radiol.2020202288

41. Blondiaux E, Parisot P, Redheuil A, Tzaroukian L, Levy Y, Sileo C, et al. Cardiac MRI with children in multisystem inflammatory syndrome associated with COVID-19. *Radiol*. (2020) 297:E283–8. doi: 10.1148/radiol.2020202288

42. Bartoszek M, Malek LA, Barczuk-Falecka M, Brzowski M. Cardiac magnetic resonance follow-up of children after pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 in children with initial cardiac involvement. *J Magn Reson Imaging*. (2022) 55:883–91. doi: 10.1002/jmri.27870

43. Sirico D, Basso A, Raffo E, Cavallero A, Castaldi B, Sabatino J, et al. Early echocardiographic and cardiac mri findings in multisystem inflammatory syndrome in children. *J Clin Med*. (2021) 10:3360. doi: 10.3390/jcm10153360

44. Prieto LM, Toral B, Llorente A, Coca D, Blázquez-Gamero D. Cardiovascular magnetic resonance imaging in children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 and heart dysfunction. *Clin Microbiol Infect*. (2021) 27:648–50. doi: 10.1016/j.cmi.2020.10.005

45. Tannoury TE, Bulbul ZR, Bitar FF. Cardiac manifestations and short-term outcomes of multisystem inflammatory syndrome in Middle Eastern children during the COVID-19 pandemic: a case series. *Cardiol Young*. (2022) 32:165–8. doi: 10.1017/S1047951121002614

46. Webster G, Patel AB, Carr MR, Rigby CK, Rychlik K, Roweley AH, et al. Cardiovascular magnetic resonance imaging in children after recovery from symptomatic COVID-19 or MIS-C: a prospective study. *J Cardiovasc Magn Reson*. (2021) 23:86. doi: 10.1186/s12968-021-00786-5

47. Hékimiian G, Kerneis M, Zeitouni M, Cohen-Aubart F, Chommeloux J, Bréchot N, et al. Coronavirus disease 2019 acute myocarditis and multisystem inflammatory syndrome in adult intensive and cardiac care units. *Chest*. (2021) 159:657–62. doi: 10.1016/j.chest.2020.08.2099

48. Chan KS, Mangione-Smith R, Burwinkle TM, Rosen M, Varni JW. The PedsQL: reliability and validity of the short-form generic core scales and Asthma Module. *Med Care*. (2005) 43:256–65. doi: 10.1097/00055650-200503000-00008

49. Pediatric Index of Emotional Distress - GL Assessment. Available at: https://www.gl-assessment.co.uk/assessments/products/paediatric-index-of-emotional-distress/ (accessed November 16, 2021).

50. Maron BJ, Zipes DP, Kovacs RJ, American Heart Association Electrocardiography and Arrhythmias Committee of Council on Clinical Cardiology, Council on Cardiovascular Disease in Young, Council on Cardiovascular and Stroke Nursing, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Preamble, Principles, and General Considerations: A Scientific Statement From the American Heart Association and American College of Cardiology. *Circulation*. (2015) 132:e256–61. doi: 10.1161/CIR.0000000000000236

51. COVID-19 Interim Guidance: Return to Sports. Available at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-interim-guidance-return-to-sports/ (accessed November 28, 2020).

52. Chowdhury D, Fremed MA, Dean P, Glickstein JS, Robinson J, Rellosa N, et al. Return to activity after SARS-CoV-2 infection: cardiac clearance for children and adolescents. *Sports Health*. (2021) 24:19417381211039746. doi: 10.1177/19417381211039746

53. Elliott N, Martin R, Heron N, Elliott J, Grimstead D, Biswas A. Infographic. Graduated return to play guidance following COVID-19 infection. *Br J Sports Med*. (2020) 54:1174–5. doi: 10.1136/bjsports-2020-102637

54. COVID-19 Interim Guidance: Return to Sports. Available at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-interim-guidance-return-to-sports/ (accessed November 25, 2020).

55. Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. *Arthritis Rheumatol*. (2022). doi: 10.1002/art.42062. [Epub ahead of print].

56. Truong DT, Trachtenberg FL, Pearson GD, Dione A, Elias MD, Friedman K, et al. The NHLBI Study on Long-term Outcomes following the Multisystem Inflammatory Syndrome in Children (MUSIC): design and objectives. *Am Heart J*. (2022) 243:43–53. doi: 10.1016/j.amjheart.2021.08.003

57. RECOVER. Available at: https://recovercovid.org/ (accessed November 15, 2021).

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Fremed and Farooqi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.